Tiziana Life Sciences Initiates Phase 2a Trial of Intranasal Foralumab For Non-Active Secondary Progressive Multiple Sclerosis
Portfolio Pulse from Benzinga Newsdesk
Tiziana Life Sciences has initiated a Phase 2a trial of intranasal Foralumab for non-active secondary progressive multiple sclerosis. The trial aims to evaluate the safety and efficacy of the treatment.
September 26, 2023 | 11:13 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Tiziana Life Sciences has initiated a Phase 2a trial for a new treatment. This could potentially impact the company's stock depending on the trial's results.
The initiation of a Phase 2a trial by Tiziana Life Sciences is a significant step in the development of their new treatment. The results of this trial could potentially have a positive or negative impact on the company's stock, depending on whether the trial is successful or not. Therefore, the short-term impact on the stock is neutral until the results of the trial are known.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 100